Cimzia

• Brands Cimzia
• Product Code: Cimzia

• Cimzia (certolizumab pegol) is a tumor necrosis factor (TNF) inhibitor, a type of biologic drug that reduces inflammation by targeting TNF-alpha, a key protein involved in the immune system’s inflammatory response. Overproduction of TNF-alpha contributes to the symptoms of several chronic autoimmune diseases.

  FDA-approved uses include:

  • Rheumatoid arthritis (RA)

  • Psoriatic arthritis (PsA)

  • Ankylosing spondylitis (AS)

  • Non-radiographic axial spondyloarthritis

  • Crohn’s disease

  • Plaque psoriasis

  How it works:

  • Cimzia binds to TNF-alpha and neutralizes its activity.

  • This helps reduce inflammation, pain, and damage to joints or the digestive tract, depending on the disease being treated.

  Unique feature:

  • Cimzia is pegylated (chemically linked to polyethylene glycol), which may allow for longer duration of action and less placental transfer—making it a potential option for use during pregnancy (with physician oversight).

  Administration:

  • Given as a subcutaneous injection, usually every 2 to 4 weeks after an initial loading dose.

  • Available in prefilled syringes or autoinjector pens.

  Common side effects:

  • Injection site reactions

  • Upper respiratory infections

  • Headache

  • Nausea

  Serious risks:

  • Increased risk of serious infections (e.g., tuberculosis)

  • Risk of certain cancers

  • Potential nervous system problems

  • Allergic reactions

  Before starting Cimzia, patients are usually screened for tuberculosis and other infections.

• Availability: In Stock

• American Diabetes Association

• Diabetes Disaster_Response Coalition storing insulin

• FDA Approved Prescription